专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0044399A3 TREATMENT OF ERECTILE DYSFUNCTIONS WITH A C-TYPE NATRIURETIC POLYPEPTIDE (CNP) AS MONOTHERAPY OR IN COMBINATION WITH PHOSPHODIESTERASE INHIBITORS 审中-公开
标题翻译：使用C型利钠肽（CNP）勃起功能障碍作为单一疗法治疗或WITH COMBINED磷酸二酯酶
公开(公告)号：WO0044399A3
公开(公告)日：2000-12-14
申请号：PCT/EP0000634
申请日：2000-01-27
申请人： FORSSMANN WOLF GEORG , MAEGERT HANS JUERGEN , STIEF CHRISTIAN , KUETHE ANDREA , UECKERT STEFAN , BECKER ARMIN
发明人： FORSSMANN WOLF-GEORG , MAEGERT HANS-JUERGEN , STIEF CHRISTIAN , KUETHE ANDREA , UECKERT STEFAN , BECKER ARMIN
IPC分类号： A61K45/06 , A61K31/444 , A61K31/496 , A61K31/519 , A61K38/22 , A61P15/10 , C07K14/58
CPC分类号： A61K38/2242 , A61K2300/00
摘要： The invention relates to medicaments containing a combination of CNP or fragments or derivatives with obtained physiological action of the CNP and phosphodiesterase inhibitors.
摘要翻译：含有CNP或具有CNP生理作用的片段或衍生物与磷酸二酯酶抑制剂的组合的药物。

3. 发明申请

WO0078328A3 USE OF GROWTH HORMONE (hGH) FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISTURBANCES 审中-公开
标题翻译：生长激素性功能障碍的治疗中（hGH）的
公开(公告)号：WO0078328A3
公开(公告)日：2002-02-28
申请号：PCT/EP0005517
申请日：2000-06-15
申请人： BECKER ARMIN JOHANNES , STIEF CHRISTIAN GEORG , UECKERT STEFAN , JONAS UDO
发明人： BECKER ARMIN JOHANNES , STIEF CHRISTIAN GEORG , UECKERT STEFAN , JONAS UDO
IPC分类号： A61K45/00 , A61K38/27 , A61P15/08 , A61P15/10 , A61K31/00 , A61K38/25 , A61K38/30 , A61K45/06 , A61P15/00
CPC分类号： A61K38/27 , A61K2300/00
摘要： The invention relates to the use of the human growth hormone (hGH, GH) either on its own or in combination with active substances which result in GH stimulation, have an effect which is analogous to GH or which promote the release of IGF-I in the production of medicaments which are used to treat sexual functional disturbances in both sexes. The invention also relates to a method for treating the above-mentioned dysfunctions.
摘要翻译：本发明涉及使用人生长激素（HGH，GH）单独或与引起GH刺激剂组合，一个GH有类似的效果，或IGF-1释放促进生产药物为两性的性功能障碍的治疗并表示对于疾病的治疗方法。

4. 发明专利

CA2295616A1 USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES 未知
公开(公告)号：CA2295616A1
公开(公告)日：1999-01-21
申请号：CA2295616
申请日：1997-07-09
申请人： FORSSMANN WOLF GEORG
发明人： JONAS UDO , TRUSS MICHAEL CARSTEN , UECKERT STEFAN , STIEF CHRISTIAN GEORG
IPC分类号： A61K31/52 , A61K31/35 , A61K31/415 , A61K31/50 , A61K31/505
摘要： The present invention pertains to the use of inhibitors of phosphodiesterase I, IV and V for the prophylaxis and treatment of prostatic diseases, in particular the use of a) 2-(2-propoxy- phenyl)-8-azapurin-6-one (zaprinast); b) dipyridamole; c) 1-(3-chlorophenylamino)-4-phenylphthalazine (M5445); d) 2 (N-(4-carboxypiperidine-6-chloro-4-(3,4- (methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355); e) 2,3-dihydro-8-hydroxy-7-nitro-1, 4-benzodioxine-2-methanol, alpha-nitrate (E 4701); f) 4 ((3,4-(methylendioxy) benzyl)amino)-6, 7,8-trimethoxy-quinazoline; g) 1-methyl-3-propyl-6- (5-(N-(4-methylmorpholino) sulfonyl)-2-ethoxyphenyl)pyrazole ¢4,5!pyrimidin-4(5H)one (sildenafil); i) 1-cyclopentyl-3-methyl-6- (4pyridinyl)pyrazolo(3, 4-d)pyrimidin-4(5H)-one (WIN 58237); j) 7-(3-(4-acetyl-3- hydroxy-2-propyl-phenoxy) -2-hydroxy-propoxy)-2-carboxy-2, 3-didehydro-chronan-4-one (FPL-557212); k) quinazolines and their trimethoxy derivatives; l) Pyrazolopyrimidones; as well as pharmacologically compatible salts thereof, quinazolines and their trimethoxy derivatives, pyrazolopyrimidones or compatible salts thereof, in local and systemic administration.

5. 发明专利

DE19935209A1 Treatment of urinary incontinence and related disorders, by increasing intracellular cyclic adenosine monophosphate concentration, e.g. using adenyl cyclase stimulant such as forskolin 未知
公开(公告)号：DE19935209A1
公开(公告)日：2001-02-08
申请号：DE19935209
申请日：1999-07-27
申请人： TRUSS MICHAEL C , UECKERT STEFAN
发明人： TRUSS MICHAEL CARSTEN , STIEF CHRISTIAN G , JONAS UDO , UECKERT STEFAN , BECKER ARMIN J , FORSSMANN WOLF-GEORG
IPC分类号： A61K31/00 , A61K31/352 , A61K31/4375 , A61K31/495 , A61K31/35
摘要： Use of intracellular cyclic adenosine monophosphate (cAMP) concentration increasing agents (I) for treating urge symptoms, urge incontinence, pollakiuria, nycturia and detrusor muscle instability, where (I) is a cellular adenyl cyclase stimulant, modulator of binding to beta 1-, beta 2- or beta 3-adrenoceptors of the urinary bladder musculature or a cellular cAMP hydrolyzing phosphodiesterase inhibitor. The use of intracellular cyclic adenosine monophosphate (cAMP) concentration increasing agents (I) is claimed for treating urge symptoms, urge incontinence, pollakiuria, nycturia and detrusor muscle instability, where (I) is selected from (a) cellular adenyl cyclase stimulants, (b) modulators of binding to beta 1-, beta 2- or beta 3-adrenoceptors of the urinary bladder musculature and (c) cellular cAMP hydrolyzing phosphodiesterase inhibitors. Alternatively (I) is replaced by cAMP analogs (II) which stimulate the phosphorylating activity of cellular cAMP-binding protein kinases and thus reduce the cytosolic calcium ion concentration. An Independent claim is included for pharmaceutical preparations comprising combinations of (I) (a)-(c).

6. 发明专利

DE19931206A1 Relaxing, or increasing cyclic adenosine monophosphate concentration in smooth muscular tissue, e.g. by administration of cAMP phosphodiesterase inhibitors, dipyridamole or sildenafil 未知
公开(公告)号：DE19931206A1
公开(公告)日：2001-01-11
申请号：DE19931206
申请日：1999-07-07
申请人： STIEF CHRISTIAN
发明人： STIEF CHRISTIAN G , UECKERT STEFAN , BECKER ARMIN , JONAS UDO , FORSSMANN WOLF-GEORG
IPC分类号： A61K31/00 , A61K31/352 , A61K31/357 , A61K31/502 , A61K31/517 , A61K31/519 , A61K31/505
摘要： The use of cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) inhibitors (I) is claimed in the production of medicaments for the relaxation of smooth muscular tissue or for increasing the cAMP concentration in smooth muscular tissue. Independent claims are included for the following: (i) the use of the following compounds (II) as for (I) above: (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-2,5-dimethyl-3-benzyl-cyclopenta (4,5)-imidazo (2,1-b) purin-4(3H)-one; (6aR,9aS)-benzyl-5,6a,7,8,9,9a-hexahydro-5-methyl-3-benzyl-cyclopenta (4,5)-imidazo (2,1-b) purin-4(3H)-one; rac-(6aR asterisk ,9aS asterisk )-5,6a,7,8,9,9a-hexahydro-5-methyl-1-benzyl-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; (6aR,9aS)-3,5-dimethyl-5,6a,7,8,9,9a-hexahydro-1-benzyl-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; rac-(6a asterisk R,9aS asterisk )-5,6a,7,8,9,9a-hexahydro-1,5-dimethyl-3-benzyl-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; rac-(6a asterisk R,9aS asterisk )-1,3-dibenzyl-5,6a,7,8,9,9a-hexahydro-5-methyl-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; rac-(6a asterisk R,9aS asterisk )-5,6a,7,8,9,9a-hexahydro-2,5-dimethyl-3-benzyl-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one;(6aR,9aS)-5,6a,7,8,9,9a-hexahydro-2,5-dimethyl-3-b enzyl-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; 2',5'-dimethyl-3'-benzyl-spiro-(cyclopentane-1,7'(8'H)-(2H) imidazo (1,2-a) pyrazolo (4,3-e) pyrimidine)-4'(5'H)-one; 7,8-dihydro-3-benzyl-2,5,7,7-tetramethyl-(2H)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; (7R)-7,8-dihydro-2,5-dimethyl-7-isopropyl-3-benzyl-(2H)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-phenyl-2-benzyl-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; rac-(6aR asterisk ,9aS asterisk )-5,6a,7,8,9,9a-hexahydro-5-methyl-3-benzyl-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; (6aR,9aS)-3,5-dimethyl-5,6a,7,8,9,9a-hexahydro-cyclopenta (4,5)-imidazo (1,2-a) pyrazolo (4,3-e) pyrimidin-4(1H)-one; 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); dipyridamole; 1-(3-chlorophenylamino)-4-phenylphthalazine; 2-(N-(4-carboxypiperidine)-6-chloro-4-(3,4-methylenedioxy)-benzyl)-ami no)-quinazoline; 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxin-2-methanol; 4-((3,4-methylenedioxy)-benzyl)-amino)-6,7,8-trimethoxy-quinazoline; 1-methyl-3'-propyl-6-(5-(N-(4-methylmorpholino)-sulfonyl)-2-ethoxyphen yl)-pyrazolo (4,5) pyrimidin-4(5H)-one (sildenafil); 2-n-butyl-5-chloro-1-(2-chlorobenzyl)-4-methylacetate-imidazole; 1-cyclopentyl-3-methyl-6-(4-pyridinyl)-pyrazolo (3,4-d) pyrimidin-4(5H)-one; 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxypropoxy)-2-carboxy -2,3-didehydro-chroman-4-one; quinazolines or their trimethoxy derivatives; or pyrazolopyrimidines and (ii) the use of sildenafil, IC 351 or BAY-9456 for the production of medicaments for the treatment of diseases in which an increase of the cAMP concentration in smooth muscular tissue.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式